NCT03322332

Brief Summary

The aim of the study is to investigate whether the expression and production of adipokines secreted by the epicardial adipose tissue correlate with the degree of coronary atherosclerosis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 23, 2017

Completed
Same day until next milestone

Study Start

First participant enrolled

October 23, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 26, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2018

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 22, 2018

Completed
Last Updated

October 26, 2017

Status Verified

October 1, 2017

Enrollment Period

3 months

First QC Date

October 23, 2017

Last Update Submit

October 23, 2017

Conditions

Keywords

adiponectinomentin-1resistinRBP4epicardial fatCoronary artery disease

Outcome Measures

Primary Outcomes (1)

  • Association between coronary artery disease and epicardial adipokines

    Comparison of the mRNA and protein production of four adipokines \[adiponectin, omentin-1, resistin, retinol binding protein-4(RBP4)\] from the epicardial adipose tissue between the territories that are supplied by LAD and RCA. This comparison will be performed in the following clusters of groups: 1. Cluster 1: NonDM-0 and DM-0 (comparison between territories that are supplied by non-stenosed coronary arteries) 2. Cluster 2: NonDM-LR and DM-LR (comparison between territories that are supplied by stenosed coronary arteries) 3. Cluster 3: NonDM-L, NonDM-R, DM-L and DM-R (comparison between a territory that is supplied by stenosed coronary artery and another territory that is supplied by non-stenosed coronary artery)

    Baseline measurement

Secondary Outcomes (1)

  • Impact of diabetes on epicardial adipokines

    Baseline measurement

Study Arms (8)

NonDM-0

Nondiabetics without significant stenoses (\> 50%) in the coronary arteries

NonDM-L

Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)

NonDM-R

Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA

NonDM-LR

Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA

DM-0

Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries

DM-L

T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA

DM-R

T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA

DM-LR

T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Individuals undergoing cardiac surgery will be recruited in this study.

You may qualify if:

  • \) Individuals undergoing cardiac surgery

You may not qualify if:

  • Age \< 18 years
  • HbA1c \> 7.0%
  • Any change of antidiabetic medication the previous 3 months before the surgery
  • GFR \< 60 mL/min/1.73 m2
  • Liver disease
  • Cancer
  • Non-treated hyperthyroidism or hypothyroidism
  • Autoimmune disease
  • Infection
  • Any change in body weight at least 5% the previous 3 months before surgery
  • Significant dehydration.
  • Taking any of the following drugs the previous 3 months before surgery: hormones, antiobesity drugs

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Ioannina

Ioannina, Greece

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Eustratios Apostolakis, Professor

    University Hospital, Ioannina

    STUDY DIRECTOR

Central Study Contacts

Eustratios Apostolakis, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Cardiologist, Postdoctoral researcher

Study Record Dates

First Submitted

October 23, 2017

First Posted

October 26, 2017

Study Start

October 23, 2017

Primary Completion

January 15, 2018

Study Completion

January 22, 2018

Last Updated

October 26, 2017

Record last verified: 2017-10

Locations